The Mechanisms Involved in Mesenchymal Stem Cell Alleviation of Sepsis-Induced Acute Lung Injury in Mice: A Pilot Study

Feng Luo†, Wei Jiang†, Yan Xu, Xue-mei Liu, Wei Wang, Wei Zhang, Congjuan Luo*

The Affiliated Hospital of Qingdao University, Shandong, China

ABSTRACT

Background: Acute lung injury is a common complication of sepsis in intensive care unit patients. Inflammation is among the main mechanisms of sepsis. Therefore, suppression of inflammation is an important mechanism for sepsis treatment. Mesenchymal stem cells (MSCs) have been reported to exhibit antimicrobial properties.

Objective: The present study investigated the effects of MSCs on sepsis-induced acute lung injury.

Methods: Male C57BL/6 mice underwent a cecal ligation and puncture (CLP) operation to induce sepsis and then received either normal saline or MSCs (1 × 10⁶ cells intravenously) at 3 hours after surgery. Survival after surgery was assessed. Lung injury was assessed by histology score, the presence of lung edema, vascular permeability, inflammatory cell infiltration, and cytokine levels in bronchoalveolar lavage fluid. Finally, we tested nuclear factor kappa-light-chain-enhancer of activated B cells activation in lung tissue.

Results: As expected, CLP caused lung injury as indicated by significant increases in the histopathology score, lung wet to dry weight ratio, and total protein concentration. However, mice treated with MSCs had amelioration of the lung histopathologic changes, lung wet to dry weight ratio, and total protein concentration. The levels of cytokines tumor necrosis factor alpha, interleukin 6, interleukin 1β, and interleukin 17 in bronchoalveolar lavage fluid were dramatically decreased after MSCs treatment. In contrast, expression of interleukin 10 was increased after MSCs treatment. Moreover, mice treated with MSCs had a higher survival rate than the CLP group. Neutrophil infiltration into bronchoalveolar lavage fluid was attenuated after MSCs injection, but the amounts of macrophages observed in the MSC group showed no significant differences compared with the CLP group. In addition, MSCs treatment significantly reduced nuclear factor kappa-light-chain-enhancer of activated B cells activation in lung tissue.

Conclusions: Based on the above findings, treatment with MSCs dampened the inflammatory response and inhibited nuclear factor kappa-light-chain-enhancer of activated B cells activation in the mouse CLP model. Thus, MSCs may be a potential new agent for the treatment of sepsis-induced acute lung injury.

(Curr Ther Res Clin Exp. 2020; 81:XXX–XXX)
tor alpha (TNF-α), interleukin (IL) 6, and IL-1β. IL-17 plays a uniquely powerful role in the inflammatory system, which mediates inflammation and induces neutrophil recruitment to inflammatory sites. IL-17 has been reported to increase in sepsis and in turn leads to parenchymal cell dysfunction and tissue damage. The release of anti-inflammatory cytokines, particularly IL-10, is related to downregulation of proinflammatory cytokines and prevention of lung injury. Although mechanisms underlying the development of ALI are not clearly understood, the number of inflammatory cells and activation of inducible transcription factors in the lungs, such as nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), is believed to lead to the development of septic ALI. Activation of NF-κB leads to the activation of various proinflammatory markers for the progression of lung inflammation.

Thus, there have been many attempts to control the inflammatory response using specific cytokine or antimediator therapies. Recently, bone marrow-derived mesenchymal stromal cells (MSCs) have become a hot topic of research, studied in several clinical settings of inflammatory diseases, including sepsis, ischemic kidney injury, and Crohn’s disease. The prominent features of MSCs include their ability to home to injured tissues, versatile paracrine signaling effects, an immunomodulatory capacity, and potential for direct antimicrobial effects. The complexity of the mechanism of the inflammatory response in sepsis-induced ALI, which is not only involved in preventing infection or inflammation, but also in limiting tissue damage, underlines the critical nature of anti-inflammatory activity. MSCs may have a therapeutic effect in sepsis-induced ALI.

Animal models play an important role in sepsis research. The cecal ligation and puncture (CLP) model is the gold standard. Therefore, in our study, we used the CLP model to elucidate the effect of MSCs treatment on sepsis-induced ALI.

**Methods**

**Animal model**

Male C57Bl/6 mice weighing 25 to 30 g were purchased from the animal center at Qingdao University (Qingdao, China). Mice were housed in a constant temperature environment a 12-hour light–dark cycle. The mice were allowed to access to food and water freely. They were acclimated for 1 week before conducting experiments. All experimental procedures were approved by the Animal Care and Use Committee of Qingdao University.

**Culture of MSCs**

C57Bl/6 mouse bone marrow-derived MSCs were purchased from Cyagen Biosciences (Sunnyvale, California) and cultured according to the supplier’s instructions. Sixth, eighth, and 10th passage MSCs were used for experiments.

**Mouse model of CLP**

CLP-induced sepsis was generated as described previously. Mice were anesthetized with 2% pentobarbital and a 1- to 2-cm midline incision was made along the linea alba of the abdominal muscle to isolate and exteriorize the cecum. Seventy-five percent of the cecum was ligated with a 4-0 silk suture, and the cecum was punctured twice with a 21 G needle. A small amount (droplet) of feces was gently extruded from the penetration holes to ensure patency. The cecum was then returned to the peritoneal cavity gently, and the abdominal incision was closed carefully with 4-0 silk sutures. In the sham group, mice underwent the same procedure but were neither ligated nor punctured.

Three hours after CLP, mice were injected with $1 \times 10^6$ MSCs in 0.2 mL normal saline via the tail vein. As a control, 0.2 mL normal saline was injected to CLP and sham mice.

**Survival study**

Survival study was carried out as a separate experiment with 20 animals in each group. After grouping, the mice in each group were observed for their survival period until 120 hours from the time of surgery.

**Animal death and tissue harvest**

The mice were put to death by cervical dislocation at 24 hours after sham or CLP surgery. The lung tissues and bronchoalveolar lavage fluid (BALF) were obtained for the different purposes, respectively.

**Histology to assess lung injury**

Right lung tissue in each group (eg, sham, CLP, and CLP + MSCs) were used in this analysis. The lung tissue was perfused with 10% formalin, and embedded in paraffin. Five-millimeter sections were prepared for hematoxylin and eosin staining. All procedures were performed according to previously published methods. A pathologist who was blinded to the experimental assignments analyzed all sections. In brief, lung histology alterations were assessed on the following parameters: a scale of 0 to 3 (0 = absent and appeared normal, 1 = light, 2 = moderate, and 3 = severe) according to the histologic features: edema, hyperemia and congestion, neutrophil margination and tissue infiltration, intra-alveolar hemorrhaging and debris, and cellular hyperplasia. Each parameter was scored from 0 to 3 based on severity. Then lung injury was assessed by the total score, which was calculated as the sum of all scores for each parameter (0–3 = normal to minimal injury, 4–6 = mild injury, 7–9 = moderate injury, and 10–12 = severe injury). The maximum score per animal was 12.

**Bacterial load determination in lungs**

To determine the pulmonary bacterial load, the lungs were harvested and equal amounts of wet tissue were homogenized and briefly centrifuged to remove gross particulate matter. Serial dilutions of tissue homogenates were prepared. A portion of each dilution was then plated on blood agar plates and incubated at 37°C for 24 hours under aerobic conditions. According to the dilution factor, the number of bacterial colonies was expressed as colony-forming units (CFUs) per gram of wet tissue.

**Lung wet to dry weight ratio**

Lung edema was assessed by calculating the ratio of lung wet to dry (W/D) weight ratio. Freshly harvested lung was washed 3 times with phosphate buffered saline at 4°C to remove residual blood, dried, and weighed to obtain the wet lung weight (W). For measurement of the dry weight (D), the tissue was then dried in an oven at 80°C for at least 24 hours. The W/D ratio was calculated as follows: $W/D \text{ ratio (\%)} = \left(\frac{\text{wet weight} - \text{dry weigh}}{\text{dry weight}}\right) \times 100$

**Total protein concentration and cell count in BALF**

BALF was obtained by washing the airways 3 times with 1.5 mL saline. The BALF was centrifuged at 1500 rpm for 10 minutes at 4°C. The supernatant was collected for total protein analysis using Tripure Isolation Reagent (Roche Diagnostics, Basel, Switzerland)
according to the manufacturer’s instructions. The cell pellet was re-suspended in phosphate buffered saline for the total cell count using a hemacytometer, and differential cell counts were performed with cytopsins by the Wright-Giemsa staining method.

**Cytokine analysis by ELISA**

Mouse TNF-α, IL-6, IL-1β, IL-17, and IL-10 were measured in BALF using commercially available enzyme-linked immunosorbent assay kits (R&D Systems, Minneapolis, Minnesota), according to the manufacturer’s instructions.

**Western blots**

Lung tissues were homogenized and total proteins were extracted using a tissue protein extraction reagent according to the manufacturer’s instructions. The protein concentration was measured using a bicinchoninic acid protein assay kit (Beyotime Biotechnology, Haimen, China). A total of 100 μg protein was separated by 15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane. Anti-p-NF-κB p65 and -inhibitor kappa B-alpha (IκB-α) antibodies (Cell Signaling Technology, Danvers, Massachusetts) were applied as primary antibodies at 4°C overnight, and horseradish peroxidase-conjugated anti-rabbit/mouse immunoglobulin G (Santa Cruz Biotechnology, Dallas, Texas) were used as secondary antibodies. Densitometry was performed using Quantity One software (Bio-Rad Laboratories, Hercules, California).

**Statistical analyses**

Data are expressed as means (SEM). Multiple comparisons of parametric data were performed using one-way analysis of variance followed by the Student-Newman-Keuls post hoc test. Survival was estimated by Kaplan-Meier analysis. Analyses were conducted using SPSS for Windows version 10.1 (SPSS, Inc, Chicago, Illinois). Statistical significance was defined as P values < 0.05.

**Results**

**Effect of treatment with MSCs on survival**

In the absence of antibiotic therapy, survival was observed for 120 hours after the CLP operation to investigate the improvement by treatment with MSCs. All sham-operated mice without the CLP operation survived, but the survival rate of the CLP group was only
30% at 120 hours (Figure 1). Treatment with MSCs significantly improved the survival rate compared with the septic mice ($P < 0.05$).

**Effects of treatment with MSCs on lung histology**

To evaluate histologic changes after MSC treatment on CLP-induced ALI, lung tissues were harvested at 24 hours after the CLP operation. No histologic alteration was observed in lung specimens of the sham group (Figure 2A). Conversely, in the CLP group, there was a severe inflammatory response characterized by hemorrhaging, alveolar congestion, thickening of the alveolar wall/hyaline membrane formations, and infiltration and aggregation of neutrophils in airspaces or vessel walls (Figure 2B). However, these inflammatory alterations were markedly attenuated in the MSCs group (Figure 2C). Consistent with these findings, histologic scores of lung tissue were significantly higher after the CLP operation (Figure 2D), and the MSCs treatment group had a significantly lower lung injury score than the CLP group.

**Effects of treatment with MSCs on the lung W/D ratio and protein content**

To evaluate changes in pulmonary vascular permeability, the lung W/D weight ratio was analyzed. As shown in Figure 3A, the lung W/D weight ratio was significantly higher at 24 hours after the CLP operation compared with the sham group ($P < 0.05$). MSCs treatment significantly decreased the lung W/D weight ratio ($P < 0.05$). As expected, mice in the CLP group had significantly higher levels of total protein in BALF than those in the sham group as shown in Figure 3B. Accordingly, the protein content after MSCs treatment was significantly reduced compared with the CLP group ($P < 0.05$).

**Effect of treatment with MSCs on bacterial load**

The CLP model is known to be associated with the development of bacteremia. To understand the mechanism of MSCs in sepsis-induced ALI mice, we examined the bacterial load in pulmonary samples at 24 hours after CLP injury. The CLP group had high CFU values, whereas the MSCs group had significantly reduced CFU values (Figure 4).
Effects of treatment with MSCs on lung inflammatory cells in BALF

Accumulation of activated inflammatory cells in the lungs correlates directly with the severity of septic ALI. To further assess the inflammatory responses in septic lungs, we examined the number of neutrophils and macrophages in BALF at 24 hours after CLP injury. As expected, the CLP operation significantly increased the number of neutrophils and macrophages in BALF compared with sham group ($P < 0.05$). In contrast, MSCs administration decreased the number of neutrophils in BALF, but there was no significant change in the number of macrophages between MSCs and CLP groups ($P > 0.05$) (Figure 5).

Effect of treatment with MSCs on inflammatory cytokines in BALF

Next, we evaluated the effects of MSCs on the production of inflammatory cytokines related to septic ALI. As illustrated in Figure 6, the concentrations of TNF-$\alpha$, IL-6, IL-1$\beta$, IL-10, and IL-17 in BALF were significantly increased in the CLP group. In contrast, MSCs treatment decreased the levels of TNF-$\alpha$, IL-6, IL-1$\beta$ and IL-17 in BALF compared with the CLP group. However, in contrast to inflammatory mediators, MSCs treatment increased the levels of the anti-inflammatory cytokine IL-10 in BALF compared with CLP mice (Figure 6).

Effects of treatment with MSCs on NF-$\kappa$B activation

To determine whether MSCs treatment has any effect on the NF-$\kappa$B pathway in the lungs, western blotting was performed to analyze the phosphorylated NF-$\kappa$B p65 and I$\kappa$B-$\alpha$ that reflect activation of NF-$\kappa$B. As shown in Figure 7, the CLP operation significantly increased I$\kappa$B-$\alpha$ and phosphorylated NF-$\kappa$B p65 compared with the sham group. However, MSCs treatment markedly decreased I$\kappa$B-$\alpha$ and phosphorylated NF-$\kappa$B p65 induced by sepsis ($P < 0.05$) (Figure 7). These results showed that MSCs inhibited NF-$\kappa$B activation in sepsis-induced ALI mice.

Discussion

In this study, we evaluated the protective effects of MSCs in the CLP-induced ALI mouse model. Consistent with a previous study, MSC administration attenuated lung inflammatory injury after the CLP operation, as revealed by the decreased lung W/D weight ratio, bacterial load, protein content, and inflammatory cells in BALF, which was associated with reduced lung histologic damage. In ad-
dition, we found that MSCs treatment markedly inhibited the release of proinflammatory cytokines in BALF. Furthermore, MSCs significantly inhibited CLP-induced NF-κB activation in lung tissues and increased the expression of anti-inflammatory cytokine IL-10. Moreover, our data support previous studies showing that MSCs improved the septic mouse survival rate, even in the presence of antibiotic therapy.21

Although many different pathogeneses are involved in the development of sepsis, bacteria are the most recognized pathogenesis. Previous studies have shown that MSCs inhibit the inflammatory responses in endotoxin-induced sepsis.22-24 However, the mechanism needed to be investigated further. Few studies have indicated that MSCs secrete antibacterial proteins/peptides such as LL-3717 and lipocalin-2,25 leading to improved bacterial clearance. Pati and colleagues26 reported that treatment with MSCs increases bacterial clearance because of enhanced phagocytic activity in host immune cells. The antimicrobial effect was explained in part by an increase in monocyte phagocytosis of MSC-treated mice. However, there is considerable debate regarding the antimicrobial effects of MSCs. Another study showed that isolated MSCs lacked the ability to directly kill Escherichia coli in vitro.27 And Li and colleagues28 reported that blocking NF-κB activity can effectively reduce acute lung injury in mice, but without compromising bacterial host defense after CLP. Many factors may account for the preservation of bacterial host defense. Fortunately, in our study, MSCs therapy significantly reduced the bacterial load in BALF, which may have contributed to the survival benefit and reduction of inflammation in sepsis-induced ALI.

Pulmonary edema is a representative symptom of sepsis-induced ALI,29 which is often caused by the loss of alveolar-capillary barrier integrity.30 The magnitude of pulmonary edema was evaluated by examining the lung W/D weight ratio. Our present study showed that MSCs significantly decreased the W/D weight ratio and protein content in BALF, which is in line with the pulmonary histopathology results indicating that MSCs obviously alleviated alveolar epithelial cell edema and decreased the percolate in alveolar cavities. These results demonstrated that MSCs suppressed the filtration of protein-rich edema into the interstitial and alveolar spaces.

It is increasingly recognized that inflammatory cytokines play important roles during sepsis-induced ALI. Indeed, proinflammatory cytokines, such as TNF-α, IL-6, and IL-1β, are the major mediators of early inflammatory responses during sepsis-induced ALI.31,32

Indeed, MSCs have an anti-inflammatory activity. Several reports have demonstrated that MSCs modulate innate and adaptive immune cells by enhancing anti-inflammatory pathways in the injured organ milieu, which is mediated by cell contact-dependent and -independent mechanisms through the release of soluble factors such as TSG-6 and PGE2.33-35 In this study, CLP-induced neutrophil infiltration in the lungs was significantly reduced by treatment with MSCs. This reduction of leukocyte accumulation was accompanied by a reduction in the production of cytokines, including TNF-α, IL-1β, IL-6, and IL-17, in MSC-treated mice. A study has reported that MSCs promote the repolarization of monocytes and/or macrophages from the type 1 phenotype (proinflammatory) to the type 2 (anti-inflammatory) phenotype characterized by high levels of IL-10 secretion in sepsis.23 However, in our study, although we found an increase of IL-10, there was no effect on the number of macrophages in BALF, which is inconsistent with previous reports. Our previous study showed that MSCs attenuate ischemic acute kidney injury by inducing regulatory T cells through splenocyte interactions.36 We also found that MSCs attenuate sepsis-induced acute kidney injury by reducing IL-17.37 MSCs...
have been shown to inhibit the differentiation of naïve T cells into Th17 cells, inhibit secretion of proinflammatory cytokine IL-17, and promote expression of IL-10 by immunosuppressive FoxP3 T regulatory cells. Therefore, we believe that treatment with MSCs for sepsis-induced AKI may be mediated through the balance of anti-inflammatory T regulatory cells and proinflammatory Th17 cells. MSCs ameliorate this potential injury through decreasing proinflammatory cytokines and increasing anti-inflammatory cytokines. In our previous study we found that MSCs mainly homed to lungs in the CLP model. These results suggested that the protective effects of MSCs on AKI may be related to the cell-to-cell contacts between MSCs and lung cells.

Additionally, NF-κB signaling plays a central role in regulation of the inflammatory response by participating in the transcription of many genes encoding cytokines and inflammatory mediators such as TNF-α, IL-6, and IL-1β.41,42 Therefore, blocking the NF-κB signaling pathway may alleviate lung injury and the inflammatory response in CLP-induced AKI mice. In recent years, several studies have demonstrated that MSCs exert significant anti-inflammatory effects. A recent study demonstrated that MSCs effectively down-regulate NF-κB signaling through secreting TSG-6 to decrease expression of proinflammatory cytokines.43,44 In the present study, we found that MSCs markedly suppressed CLP-induced nuclear accumulation of p-NF-κB p65 and IκB-α. Based on these results, MSCs may exert AKI treatment effects by blocking the release of inflammatory factors and inhibiting activation of the NF-κB pathway.

There are some limitations in our study. Our previous study reported that MSCs mainly homed to the lungs, although we observed a protective effect of MSCs on sepsis-induced AKI. However, the mechanism by which MSCs protected against sepsis-induced AKI was still unclear, which may be transdifferentiation or endocrine mechanisms. We have reported that MSCs protect against sepsis-induced AKI in which MSCs rarely homed to the kidney. Therefore, we need to research further to verify whether MSCs effects are mediated through different mechanisms for protection against sepsis-induced AKI and AKI. In this study, we found an increase of IL-10 and reduction of IL-17. However, the relationship between these changes needs further study.

Conclusions

Our study demonstrated that treatment with MSCs protects against sepsis-induced AKI. The mechanism may be mediated through the balance between sepsis-induced pulmonary proinflammatory cytokines and anti-inflammatory cytokines partially through blockade of the NF-κB signaling pathway. Overall, MSCs may have potential preventive and therapeutic effects to protect against inflammatory responses in sepsis-induced AKI.

Acknowledgment

This work was supported by the Chinese National Natural Science Foundation (grant Nos. 81700585, 81170688, 81470973, and 81770679) and the Innovation Program of Qingdao Science and Technology (grant No. 19-6-2-52-cg).

The authors thank M. Arico from Liwen Bianji, Edanz Group China (www.liwenbianji.cn/ac) for editing the English text of a draft of this manuscript.

The authors also thank Jie Shao, PhD, for providing review and editing.

References

1. Armstrong BA, Betzold RD, May AK. Sepsis and Septic Shock Strategies. Surg Clin North Am. 2017;97:1339–1379.

2. Lin MM, Dellinger RP, Townsend SR, Linde-Zwirble WT, Marshall JC, Bion J, Schorr C, Artigas A, Ramsay G, Beale R, et al. The Surviving Sepsis Campaign: Results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med. 2010;36:222–231.

3. Hough CL, Hirledge MS. Long-term outcome after acute lung injury. Crit Care Crit Care. 2012;18:8–15.

4. Hirledge MS, Cheung AM, Tansey CM, Mattey-Martyn A, Diaz-Granados N, Al-Sadi F, Cooper AB, Guest CB, Mazzer CD, Mehta S, et al. One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med. 2003;348:683–693.

5. Reiss LK, Uhlig U, Uhlig S. Mechanisms and models of lung injury induced by cytokines. Eur J Cell Biol. 2012;91:590–601.

6. Reiss LK, Schuppert A, Uhlig S. Inflammatory processes during acute respiratory distress syndrome: a complex system. Curr Opin Crit Care. 2017 Nov 15.

7. Riedemann NC, Neff TA, Guo RF, Bernacki KD, Laudes IJ, Sarma JV, Lamberjs JD, Ward PA. Protective effects of IL-6 blockade in sepsis are linked to reduced c5a receptor expression. J Immunol. 2010;184:700–703.

8. Reddy AR, Srivastava SK, Ramana KV. Anti-inflammatory effect of aludse reductive inhibition in murine polymicrobial sepsis. Cytokine. 2009;48:170–176.

9. Song HW, Yang C, Liu W, Liu XW, Liu Z, Gao F. Interleukin-17A Plays the Same Role on Mice Acute Lung Injury Respectively Induced by Lipopolysaccharide and Pararquet. Inflammation. 2017;40:1509–1519.

10. Goodman RB, Pugin J, Lee JS, Matthay MA. Cytokine-mediated inflammation in acute lung injury. Cytokine Growth Factor Rev. 2003;14:523–535.

11. Bhatia M, Zemans RK, Johnson S. Role of chemokines in the pathogenesis of acute lung injury. Am J Respir Cell Mol Biol. 2012;46:566–572.

12. Cho YB, Park KJ, Yoon SN, Song KH, Kim DS, Jung SH, Kim M, Jeong HY, Yu CS. Long-term results of adipose-derived stem cell therapy for the treatment of Crohn’s fistula. Stem Cells Transl Med. 2015;4:532–537.

13. Crisostomo PR, Markel TA, Wang Y, Meldrum DR. Surgically relevant aspects of stem cell paracrine effects. Surgery. 2008;141:577–581.

14. Wei RL, Manukyan MC, Herrmann JL, Balarabani AM, Pooyner JA, Wang Y, Meldrum DR. The immunomodulatory properties of mesenchymal stem cells: Implications for surgical disease. J Surg Res. 2011;167:78–86.

15. Krasnodembskaya A, Song Y, Fang X, Gupta N, Serikov I, Lee JW, Matthay MA. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells. 2010;28:2229–2238.

16. Chavakis E, Urbich C, Dimmeler S. Honigman and engraving of progenitor cells: A prerequisite for cell therapy. J Mol Cell Cardiol. 2008;45:514–522.

17. Hubbard WJ, Choudhry M, Schwacha MC, Kerby JD, Rue 3rd IW, Bland KI, Chaudry IH. Cecal ligation and puncture. Shock. 2005;24:52–57.

18. Zhang A, Pan W, Lv J, Wu H. Protective Effect of Amygudalin on LPS-Induced Acute Lung Injury by Inhibiting NF-κB and NLRP3 Signaling Pathways. Inflammation. 2017;40:745–751.

19. González-Rey E, Anderson P, González MA, Rico L, Bischer D, Delgado M. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut. 2009;58:929–939.

20. Nishimura K, Leelahavanichkul A, Yare A, Mayer B, Parmelee A, Doi K, Robey PG, Leelahavanichkul K, Koller BH, Brown JM, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase interleukin-10 production. Nat Med. 2009;15:42–49.

21. Mei SH, Haimsija JJ, Dos Santos CC, Deng Y, Lai PF, Slutsky AS, Liles WC, Stewart DJ. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med. 2010;182:1047–1057.

22. Krasnodembskaya A, Samaranzi G, Song Y, Zhuo H, Su X, Lee JW, Gupta N, Petrinii M, Matthay MA. Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes. Am J Physiol Lung Cell Mol Physiol. 2012;302.1.I003–1.I013.

23. Gupta N, Krasnodembskaya A, Kapetanaki M, Mouded M, Tan X, Serikov I, Matthay MA. Mesenchymal stem cells enhance survival and bacterial clearance in murine Escherichia coli pneumonia. Thorax. 2012;67:533–539.

24. Pati S, Gerber MH, Menge TD, Wataha KA, Zhao Y, Baumgartner JA, Zhao J, Letourneau PA, Huby MP, Baer LA, et al. Bone marrow derived mesenchymal stem cells inhibit inflammation and preserve vascular endothelial integrity in the lungs after hemorrhagic shock. PLoS One. 2011;6:e25271.

25. González-Rey E, Anderson P, González MA, Rico L, Bischer D, Delgado M. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut. 2009;58:929–939.

26. Hui LS, Wei Han, Vasily Poloushkin, Fiona E Yull, Brahim H Segal, Can-Mao Xie, Timothy S Blackwell. NF-κB Inhibition after Cecal Ligation and Puncture Reduces Sepsis-Associated Lung Injury without Altering Bacterial Host Defense. Mediators Inflamm. 2013;2013:503213.

27. Li H, Qian Z, Li J, Han X. Effects of early administration of a novel anti-cholinergic drug on acute respiratory distress syndrome induced by sepsis. Med Sci Monit. 2011;17:BR319-BR325.
30. Tsaka S, Hasegawa N, Ishizaka A. Pharmacology of acute lung injury. *Pulm Pharmacol Ther*. 2002;15:83–95.
31. Takaoka Y, Goto S, Nakano T, Tseng HP, Yang SM, Kawamoto S, Ono K. Chen CL. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) prevents lipopolysaccharide (LPS)-induced, sepsis-related severe acute lung injury in mice. *Sci Rep*. 2014;4:5204.
32. Bhargava R, Altmann CJ, Andres-Hernando A, Webb RG, Okamura K, Yang Y, Falk S, Schmidt EP, Faubel S. Acute lung injury and acute kidney injury are established by four hours in experimental sepsis and are improved with pre, but not post, sepsis administration of TNF-α antibodies. *Plos One*. 2013;8:e79037.
33. Pistoia V, Raffaghello L. Mesenchymal stromal cells and autoimmunity. *Int Immunol*. 2017;29:49–58.
34. Larose C, Gibot S, Reppel L, Bensoussan D. Concise Review: Mesenchymal Stromal/Stem Cells: A New Treatment for Sepsis and Septic Shock? *Stem Cells*. 2017;30.
35. Danchak S, Ylostalo JH, Hossain F, Sorge R, Ramsey A, Bonvillain RW, Lasky JA, Bunnell BA, Welsh DA, Prockop DJ, et al. Human multipotent stromal cells attenuate lipopolysaccharide-induced acute lung injury in mice via secretion of tumor necrosis factor-alpha-induced protein 6. *Stem Cell Res Ther*. 2011;2:27.
36. Hu J, Zhang L, Wang N, Ding R, Cui SY, Zhu F, Xie YS, Sun XF, Wu D, Hong Q, et al. Mesenchymal stem cells attenuate ischemic acute kidney injury by inducing regulatory T cells through splenocyte interactions. *Kidney Int*. 2013;84:521–531.
37. Luo CJ, Zhang FJ, Zhang L, Geng YQ, Li QG, Hong Q, Fu B, Zhu F, Cui SY, Feng Z, et al. Mesenchymal stem cells ameliorate sepsis-associated acute kidney injury in mice. *Shock*. 2014;41:123–129.
38. Duffy MM, Pindjakova J, Hanley SA, McCarthy C, Weidhofer GA, Sweeney EM, English K, Shaw G, Murphy JM, Barry FP, et al. Mesenchymal stem cell inhibition of T-helper 17 cell- differentiation is triggered by cell-cell contact and mediated by prostaglandin E2 via the EP4 receptor. *Eur J Immunol*. 2011;41:2840–2851.
39. Ghannam S, Pène J, Moquet-Torcy G, Jorgensen C, Yssel H. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. *J Immunol*. 2010;185:302–312.
40. Sun Y, Deng W, Geng L, Zhang L, Liu R, Chen W, Yao G, hang ZH, Feng X, Gao X, et al. Mesenchymal stem cells from patients with rheumatoid arthritis display impaired function in inhibiting Th17 cells. *J Immunol Res*. 2015;2015.
41. Cruz FF, Borg ZD, Goodwin M, Coffey AL, Wagner DE, Rocco PR, Weiss DJ. CD11b+ and Sca-1+ Cells Exert the Main Beneficial Effects of Systemically Administered Bone Marrow-Derived Mononuclear Cells in a Murine Model of Mixed Th2/Th17 Allergic Airway Inflammation. *Stem Cells Transl Med*. 2016;5:488–499.
42. Su P, Liu X, Pang Y, Liu C, Li R, Zhang Q, Liang H, Wang H, Li Q, The archaic roles of the lamprey NF-κB (lj-NF-κB) in innate immune responses. *Mol Immunol*. 2017;92:21–27.
43. Feng G, Jiang ZY, Sun B, Fu J, Li TZ. Erratum to: Fisetin Alleviates Lipopolysaccharide-Induced Acute Lung Injury via TLR4-Mediated NF-κB Signaling Pathway in Rats. *Inflammation*. 2017;40:1813.
44. Choi H, Lee RH, Razhanov N, Oh JY, Prockop DJ. Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-κB signaling in resident macrophages. *Blood*. 2011;118:330–338.